Clinical Professor of Neurology, UCSF
Neurology
Dr. Douglas S. Goodin, MD
|
|
Give Review
Douglas Goodin practices Neurology. He over the years received 2 awards: "America's Top Doctors" and "Super Doctor". Douglas S. Goodin, MD is a published physician. He has 96 publications published. The most current publication "Interferon beta treatment for multiple sclerosis." Douglas S. Goodin accepts Medicare payments and is listed with Medicare.gov.
Publications
- Predictors of Disease activity in 857 patients with MS treated with interferon beta-1b.
- A comparative analysis of Patient-Reported Expanded Disability Status Scale tools.
- Spinal cord gray matter atrophy correlates with Multiple sclerosis disability.
- Precision medicine in chronic Disease management: The multiple sclerosis BioScreen.
- Patient centered decision making: Use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
- Safety and efficacy of fingolimod in patients with relapsing-remitting Multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
- Patient preferences for attributes of Disease modifying Therapies: Results of a choice based conjoint analysis.
- The use of interferon Beta and glatiramer acetate in Multiple sclerosis.
- The genetic and environmental bases of complex human-Disease: extending the utility of twin-studies.
- Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
- Response to GS Gronseth and E Ashman.
- Evidence-based medicine: promise and pitfalls.
- Retinal Axonal Loss Begins Early in the Course of Multiple Sclerosis and Is Similar between Progressive Phenotypes.
- Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.
- Severe hypercalcemia following vitamin d supplementation in a patient with Multiple sclerosis: a note of caution.
- Neutralizing antibodies to interferon beta-1b Multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
- Switching multiple sclerosis patients with breakthrough Disease to second-line therapy.
- Pilot trial of low-dose naltrexone and quality of life in Multiple sclerosis.
- Results of using a wireless inertial measuring system to quantify Gait motions in control subjects.
- Magnetic resonance imaging as a surrogate for treatment effect on Multiple sclerosis relapses.
- The causal cascade to Multiple sclerosis: a model for MS pathogenesis.
- Disease-modifying therapy in multiple sclerosis: update and clinical implications.
- The impact of war-stress on MS exacerbations.
- A randomized study of two interferon-beta treatments in relapsing-remitting Multiple sclerosis.
- Magnetic resonance imaging as a surrogate outcome measure of disability in Multiple sclerosis: have we been overly harsh in our assessment?
- Overdiagnosis of Multiple sclerosis by magnetic resonance imaging.
- Relationship between Multiple sclerosis exacerbations and stress.
- Stimulus recognition and its relationship to the Cerebral event-related potential.
- Disease-modifying Therapies for Multiple Sclerosis.
- Single Nucleotide Polymorphism (SNP)-Strings: An Alternative Method for Assessing Genetic Associations.
- The epidemiology of multiple sclerosis: insights to Disease pathogenesis.
- Glucocorticoid treatment of Multiple sclerosis.
- The return of natalizumab: weighing benefit against risk.
- Mutant of bacteriophage T4D affecting expression of many early genes.
- Marijuana and Multiple sclerosis.
- The 2nd world congress on controversies in neurology.
- The use of MRI in the diagnosis of Multiple sclerosis.
- 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting Multiple sclerosis: a prospective, randomised, multicentre study.
- Age at disability milestones in Multiple sclerosis and history of Multiple sclerosis: a unifying concept.
- Interferon ?-1b and glatiramer acetate effects on permanent black hole evolution.
- Comparative studies of glatiramer acetate and interferon beta.
- Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting Multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENC...
- Mapping Multiple sclerosis susceptibility to the HLA-DR locus in African Americans.
- IFCN recommended standards for Brain-stem auditory evoked potentials. Report of an IFCN committee. International Federation of Clinical Neurophysiology.
- Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing Multiple sclerosis: the EVIDENCE Study.
- IFCN recommended standards for long-latency auditory event-related potentials. Report of an IFCN committee. International Federation of Clinical Neurophysiology.
- IFCN recommended standards for short latency somatosensory evoked potentials. Report of an IFCN committee. International Federation of Clinical Neurophysiology.
- Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting Multiple sclerosis: a m...
- Response to interferon beta-1a treatment in African American Multiple sclerosis patients.
- Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
- Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Co...
- Interferon-beta therapy in Multiple sclerosis: evidence for a clinically relevant dose response.
- Long-latency Cerebral event-related potentials in multiple sclerosis.
- Studies of the human stretch reflex.
- Assessment: prevention of post-lumbar puncture Headaches: report of the therapeutics and technology assessment subcommittee of the american academy of neurology.
- Therapeutic developments in Multiple sclerosis.
- Clinical utility of surface EMG: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology.
- The cladribine trial in secondary progressive MS: response.
- Cognitive event-related potentials. The International Federation of Clinical Neurophysiology.
- Somatosensory evoked potentials. The International Federation of Clinical Neurophysiology.
- Changes of forearm EMG and cerebral evoked potentials following sudden muscle stretch in patients with Huntington's Disease.
- The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurol...
- Survey of Multiple sclerosis in northern California. Northern California MS Study Group.
- Order effects in response times of parkinsonian patients and normal controls.
- Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in Multiple sclerosis.
- Interferon beta treatment for Multiple sclerosis.
- Simple and choice reaction time in Parkinson''s Disease.
- A questionnaire to assess neurological impairment in Multiple sclerosis.
- Cerebral accompaniments to simple and choice reaction tasks in Parkinson''s Disease.
- Event-related potentials in the study of sensory Discrimination and motor response in simple and choice reaction tasks.
- Cognitive event-related potentials.
- The decision to make a movement: neurophysiological insights.
- Changes of forearm EMG and cerebral evoked potentials following sudden muscle stretch during isometric contractions in patients with Parkinson''s Disease.
- Response compatibility and the relationship between event-related potentials and the timing of a motor response.
- Nonrandom behavior in a reaction-time time series.
- Comparison of late components in simultaneously recorded event-related electrical potentials and event-related magnetic fields.
- Response times and handedness in simple reaction-time tasks.
- Side effect profile of interferon beta-1b in MS: results of an open label trial.
- Neural processing in a three-choice reaction-time task: a study using Cerebral evoked-potentials and single-trial analysis in normal humans.
- Expectancy and response strategy to sensory stimuli.
- Treatment of Optic neuritis.
- In vivo detection of myelin phospholipids in Multiple sclerosis with phosphorus magnetic resonance spectroscopic imaging.
- Biochemical alterations in Multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging.
- Late electromyographic activity following stretch in human forearm muscles: physiological role.
- The frontal N30 component of the median-derived SEP in patients with predominantly unilateral Parkinson's Disease.
- Task-dependent hemisphere asymmetries of the visual evoked potential.
- Acute syphilitic meningitis. Its occurrence after clinical and serologic cure of secondary syphilis with penicillin G.
- Electrophysiologic evaluation of Dementia.
- Electrophysiological differences between demented and nondemented patients with Parkinson's Disease.
- Subclasses of event-related potentials: response-locked and stimulus-locked components.
- P300 latency as a biologic marker of Dementia.
- Sensory discrimination and its relationship to the Cerebral processing of infrequent stimuli.
- Treatment of Parkinson's Disease with ciladopa.
- Electrophysiological evidence of visual processing in a blind field.
- Dermatomal somatosensory evoked potentials in lumbosacral root compression.
Schools
University of California At Irvine California College of Medicine amp Surgery
Procedures Preformed
- EMG (Electromyography)
- Non-Cosmetic Chemodenervation
Conditions Treated
- Alzheimer's Disease
- Anterior Horn Disease
- Ataxia
- Bell's Palsy
- View All
Doctors Specialties
- Clinical Neurophysiology
- Neurology
Accepted Insurances
Awards
- America's Top Doctors
- Super Doctor
Hospital
-
San Francisco General Hospital and Trauma Center -
San Francisco VA Medical Center -
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1063507184 | |
| NPPES Provider LastName | GOODIN | |
| NPPES Provider FirstName | DOUGLAS | |
| NPPES Provider ZIPCode | 94117 | |
| NPPES Provider State | CA | |
| Specialty Description | Neurology | |
| Total Claim Count | 558.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 44.0 | |
| Percent Opioid Claims | 7.89 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1063507184 |
| Last Name Of The Provider | GOODIN |
| First Name Of The Provider | DOUGLAS |
| View All |
Similar Doctors
|
|
Dr. Jonathan S. Katz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tina T. Shih, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maya Katz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John W. Engstrom, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Aminoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard A. Cuneo, MD |
|
|
Dr. Nerissa U. Ko, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William J. Marks Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suzee E. Lee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erik C. Johnson, MD |
|
|
Dr. Heidi E. Kirsch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce Miller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Oldham, MD
This Doctor is OpenDoctor Recommended.
|